Are you Dr. Crombez?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 48 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10833 Le Conte Ave
12-441 Mdcc
Los Angeles, CA 90095Phone+1 310-206-3952Fax+1 310-206-0209- Is this information wrong?
Summary
- Dr. Eric Crombez, MD is a medical geneticist in Los Angeles, California.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 2000 - 2005
Wayne State University School of MedicineClass of 2000
Clinical Trials
- Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase Start of enrollment: 2007 Jul 25
- Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) Start of enrollment: 2012 Feb 02
Publications & Presentations
PubMed
- 137 citationsEfficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controll...Friedrich K. Trefz, Barbara K. Burton, Nicola Longo, Mercedes Martinez Pardo Casanova, Daniel Gruskin, Alex Dorenbaum, Emil D. Kakkis, Eric Crombez, Dorothy K. Grange,...> ;The Journal of Pediatrics. 2009 May 1
- 33 citationsClinical and molecular heterogeneity in patients with the cblD inborn error of cobalamin metabolism.Isabelle R. Miousse, David Watkins, David Coelho, Tony Rupar, Eric Crombez, Eric Vilain, Jonathan A. Bernstein, Tina M. Cowan, Christopher Lee-Messer, Gregory M. Enns,...> ;The Journal of Pediatrics. 2009 Apr 1
- 70 citationsSafety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaPhillip Lee, Eileen P. Treacy, Eric Crombez, Melissa P. Wasserstein, Lewis Waber, Jon A. Wolff, Udo Wendel, Alex Dorenbaum, Judith Bebchuk, Heidi Christ-Schmidt, Margr...> ;American Journal of Medical Genetics. Part A. 2008 Nov 15
- Join now to see all
Press Mentions
Gene Therapy Redosing Gains Traction as Need Grows and Novel Strategies EmergeOctober 20th, 2021- Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramApril 22nd, 2021
- Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson DiseaseDecember 9th, 2020
- Join now to see all
